Coeptis Receives Shareholder Approval Towards Z Squared Merger

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. has received shareholder approval for its merger with Z Squared Inc., which will result in Z Squared becoming a wholly owned subsidiary of Coeptis [1][2]. Company Overview - Coeptis is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4]. - The company operates through its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies [4]. Therapeutic Portfolio - Coeptis's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology [5]. - The company is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and the Karolinska Institute [5]. Technology Division - Coeptis has established a Technology Division aimed at enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [6]. Z Squared Overview - Z Squared is a digital infrastructure company focused on securing the Dogecoin and Litecoin networks through institutional-scale mining operations [8]. - Upon merger completion, Z Squared plans to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa, positioning itself as the largest publicly traded pure-play Dogecoin miner in the U.S. [8]. Operational Model - Z Squared emphasizes efficiency and risk management, converting mined assets to USD or stablecoins typically within 24 hours, aligning with a cash-flow-focused strategy [9]. - The company is led by a team with extensive expertise in cryptocurrency mining operations and infrastructure management [9].

ptis Therapeutics -Coeptis Receives Shareholder Approval Towards Z Squared Merger - Reportify